Sunday, May 11, 2025 5/11/2025

Montana Cancer Consortium: An Inclusive and Collaborative Approach to Clinical Trial Accrual and Cancer Care Delivery Research across Montana, Idaho and Wyoming

Award Number: UG1CA189872
ORGANIZATION: NATIONAL CANCER INSTITUTE
OPDIV: NIH
AWARD CLASS: COOPERATIVE AGREEMENT
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

Group Awards By:

View Award Description

Montana Cancer Consortium: An Inclusive and Collaborative Approach to Clinical Trial Accrual and Cancer Care Delivery Research across Montana, Idaho and Wyoming - PROJECT SUMMARY The Montana Cancer Consortium (MCC) is an independent, nonprofit organization whose mission is to bring state-of-the-art cancer care to Montana, Idaho, and Wyoming through National Cancer Institute (NCI) sponsored clinical research. MCC coordinates, supports and improves the activities of physicians and other cancer care professionals, cancer centers and hospitals across the service area to maximize patient access to the highest levels of cancer care with a focus on access to clinical trials. In addition, MCC helps to design and influence cancer care delivery research through continued participation that informs and speeds validated care innovations into clinical practice. The region has been characterized as `mega-rural' with limited access to care due to the vastness of the geography, lack of university-based treatment and research facilities, and lack of primary care providers. Montana, Idaho and Wyoming are home to seven, five, and one American Indian Reservations respectively, where issues of poverty, distance, and cultural taboos surrounding cancer care discussion and treatment create unique disparities to prevention, early diagnosis, treatment and survivorship of cancer. The overall goal of MCC is to increase access to clinical trials in the service area while improving the delivery of cancer care through research. This is accomplished through inclusiveness of membership, communication, education, a commitment to quality, and participation in national clinical trial initiatives. The MCC NCORP Community Site consists of 10 primary affiliate sites and nine sub-affiliates that collectively serve nearly two million residents in an area covering over 200,000 square miles. Membership includes 60 oncology investigators representing all cancer care specialty areas. MCC is a member in good standing with the four adult research bases, and is poised to provide and support expanded access to state-of-the-art cancer treatment, control, prevention, screening, surveillance and care delivery through NCI-sponsored clinical trials. Strong leadership, an involved network of member physicians and dedicated affiliate sites strengthens MCC as an NCORP Community Site.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2024 ( Subtotal = $664,153 )
2024	2024	MONTANA CANCER CONSORTIUM	2132 BROADWATER AVE STE A1	BILLINGS	MT	59102	YELLOWSTONE	USA	Cancer Control	000	11	7/24/2024	NON-COMPETING CONTINUATION	$664,153
														Subtotal = $664,153

Issue Date FY: 2023 ( Subtotal = $1,069,045 )
2023	2023	MONTANA CANCER CONSORTIUM	2132 BROADWATER AVE	BILLINGS	MT	59102	YELLOWSTONE	USA	Cancer Control	000	10	8/3/2023	NON-COMPETING CONTINUATION	$1,069,045
2023	2023	MONTANA CANCER CONSORTIUM	2132 BROADWATER AVE	BILLINGS	MT	59102	YELLOWSTONE	USA	Cancer Control	001	10	8/29/2023	NON-COMPETING CONTINUATION	$0
														Subtotal = $1,069,045

Issue Date FY: 2022 ( Subtotal = $1,063,933 )
2022	2022	MONTANA CANCER CONSORTIUM INC	2132 BROADWATER AVE STE A1	BILLINGS	MT	59102	YELLOWSTONE	USA	Cancer Control	000	9	8/1/2022	NON-COMPETING CONTINUATION	$1,063,933
														Subtotal = $1,063,933

Issue Date FY: 2021 ( Subtotal = $972,381 )
2021	2021	MONTANA CANCER CONSORTIUM INC	2132 BROADWATER AVE STE A1	BILLINGS	MT	59102	YELLOWSTONE	USA	Cancer Control	000	8	8/5/2021	NON-COMPETING CONTINUATION	$972,381
														Subtotal = $972,381

Issue Date FY: 2020 ( Subtotal = $881,991 )
2020	2020	MONTANA CANCER CONSORTIUM INC	2132 BROADWATER AVE STE A1	BILLINGS	MT	59102	YELLOWSTONE	USA	Cancer Control	002	7	8/13/2020	NON-COMPETING CONTINUATION	$881,991
2020	2019	MONTANA CANCER CONSORTIUM INC	2132 BROADWATER AVE STE A1	BILLINGS	MT	59102	YELLOWSTONE	USA	Cancer Control	001	6	2/10/2020	COMPETING CONTINUATION	$125,723
2020	2018	MONTANA CANCER CONSORTIUM INC	2132 BROADWATER AVE STE A1	BILLINGS	MT	59102	YELLOWSTONE	USA	Cancer Treatment Research	000	5	2/10/2020	NON-COMPETING CONTINUATION	-$125,723
														Subtotal = $881,991

Issue Date FY: 2019 ( Subtotal = $872,332 )
2019	2019	MONTANA CANCER CONSORTIUM INC	2132 BROADWATER AVE STE A1	BILLINGS	MT	59102	YELLOWSTONE	USA	Cancer Control	001	6	8/16/2019	COMPETING CONTINUATION	$0
2019	2019	MONTANA CANCER CONSORTIUM INC	2132 BROADWATER AVE STE A1	BILLINGS	MT	59102	YELLOWSTONE	USA	Cancer Control	000	6	8/9/2019	COMPETING CONTINUATION	$872,332
														Subtotal = $872,332

Issue Date FY: 2018 ( Subtotal = $943,439 )
2018	2018	MONTANA CANCER CONSORTIUM INC	2132 BROADWATER AVE STE A1	BILLINGS	MT	59102	YELLOWSTONE	USA	Cancer Treatment Research	001	5	9/14/2018	NON-COMPETING CONTINUATION	$194,640
2018	2018	MONTANA CANCER CONSORTIUM INC	2132 BROADWATER AVE STE A1	BILLINGS	MT	59102	YELLOWSTONE	USA	Cancer Treatment Research	000	5	7/30/2018	NON-COMPETING CONTINUATION	$748,799
														Subtotal = $943,439

Issue Date FY: 2017 ( Subtotal = $706,794 )
2017	2017	MONTANA CANCER CONSORTIUM INC	2132 BROADWATER AVE STE A1	BILLINGS	MT	59102	YELLOWSTONE	USA	Cancer Treatment Research	000	4	7/28/2017	NON-COMPETING CONTINUATION	$665,794
2017	2017	MONTANA CANCER CONSORTIUM INC	2132 BROADWATER AVE STE A1	BILLINGS	MT	59102	YELLOWSTONE	USA	Cancer Treatment Research	001	4	8/14/2017	NON-COMPETING CONTINUATION	$41,000
														Subtotal = $706,794

Issue Date FY: 2016 ( Subtotal = $611,042 )
2016	2016	MONTANA CANCER CONSORTIUM	90 POLY DRIVE SUITE 2	BILLINGS	MT	59101	YELLOWSTONE	USA	Cancer Treatment Research	000	3	8/19/2016	NON-COMPETING CONTINUATION	$611,042
														Subtotal = $611,042

Issue Date FY: 2015 ( Subtotal = $692,500 )
2015	2015	MONTANA CANCER CONSORTIUM	90 POLY DRIVE SUITE 2	BILLINGS	MT	59101	YELLOWSTONE	USA	Cancer Treatment Research	001	2	9/9/2015	NON-COMPETING CONTINUATION	$62,500
2015	2015	MONTANA CANCER CONSORTIUM	90 POLY DRIVE SUITE 2	BILLINGS	MT	59101	YELLOWSTONE	USA	Cancer Treatment Research	000	2	7/31/2015	NON-COMPETING CONTINUATION	$630,000
														Subtotal = $692,500

Issue Date FY: 2014 ( Subtotal = $730,000 )
2014	2014	MONTANA CANCER CONSORTIUM	90 POLY DRIVE SUITE 2	BILLINGS	MT	59101	YELLOWSTONE	USA	Cancer Treatment Research	000	1	7/31/2014	NEW	$630,000
2014	2014	MONTANA CANCER CONSORTIUM	90 POLY DRIVE SUITE 2	BILLINGS	MT	59101	YELLOWSTONE	USA	Cancer Treatment Research	001	1	9/19/2014	NEW	$100,000
														Subtotal = $730,000

Grand Total All Awards = $9,207,610

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Montana Cancer Consortium: An Inclusive and Collaborative Approach to Clinical Trial Accrual and Cancer Care Delivery Research across Montana, Idaho and Wyoming

Award Number: UG1CA189872

ORGANIZATION: NATIONAL CANCER INSTITUTE

OPDIV: NIH

AWARD CLASS: COOPERATIVE AGREEMENT

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer